Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …

Extrachromosomal circular DNA (eccDNA), ranging in size from tens to millions of base
pairs, is independent of conventional chromosomes. Recently, eccDNAs have been …

Background Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer
(NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth …

PURPOSE Although several agents targeting epidermal growth factor receptor (EGFR) exon
20 insertions (ex20ins) have recently been approved by the US Food and Drug …

Epidermal growth factor receptor (EGFR) mutation is one of the key oncogenic mutations in
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …

Carcinoma of the lung is among the most common types of cancer globally. Concerning its
histology, it is categorized as a non-small cell carcinoma (NSCLC) and a small cell cancer …

Objectives Several preclinical data proposed a potential efficacy of osimertinib, a third-
generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins) …

Epidermal growth factor receptor (EGFR) mutation is the most common driver mutation in
non-small cell lung cancer (NSCLC). The first-line therapy for advanced NSCLC patients …

Background Furmonertinib is a novel third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). A phase Ib study (FAVOUR, NCT04858958) initially …

Resistance mechanisms to osimertinib and emerging therapeuti... : Current Opinion in
Oncology Resistance mechanisms to osimertinib and emerging therapeutic strategies in …